In the lab, the researchers found that NXP800 slowed the growth of prostate cancer cells—even for cells which were resistant to the hormone therapy enzalutamide. In biopsies of patients with ...

Trusted source of information on Prostate Health that includes articles, news, videos, animations, quizzes, calculators and ...

The drug is already approved to treat non-metastatic castration-resistant prostate cancer (CRPC), but expansion into hormone-sensitive prostate cancer could unlock a sizeable new market for the drug.

The main finding of the observational study, published in the journal Neurology, suggests that alpha-blocker drugs used to treat urinary symptoms caused by an enlarged prostate gland may reduce ...

"Prostate cancer: Three drug trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith ...

The trial will enroll 80 patients and aims to determine if opaganib can enhance the effectiveness of darolutamide, a treatment for prostate cancer which often develops resistance to standard care.

These findings demonstrate the drug’s potential to significantly slow the progression of hormone-resistant prostate cancer. The study also uncovered how NXP800 works on a molecular level.

The new urine test looks at 18 genes that are linked to high-risk prostate cancer. Previous research showed that MPS2 could ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis, as well as prognostic and predictive biomarkers, may further ...

The LinkedIn co-founder is starting Manas AI with “The Emperor of All Maladies” author Siddhartha Mukherjee.